NCT00053807 - Interleukin-2, Interferon Alfa, and Fluorouracil Compared With Observation in Treating Patients Who Have Undergone Surgery for Kidney Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 1998

Primary Completion Date

January 31, 2004

Conditions

Kidney Cancer

Interventions

BIOLOGICAL

aldesleukin

BIOLOGICAL

recombinant interferon alfa

DRUG

fluorouracil

PROCEDURE

adjuvant therapy

Trial Locations (17)

1125

National Institute of Oncology, Budapest

8500

AZ Groeninge - Campus St. Maarten, Kortrijk

21100

Ospedale di Circolo e Fondazione Macchi, Varese

30196

Rambam Medical Center, Haifa

35340

Dokuz Eylul University School of Medicine, Izmir

81190

Marmara University Hospital, Istanbul

A-1100

Kaiser Franz Josef Hospital, Vienna

B-9300

Onze Lieve Vrouw Ziekenhuis Aalst, Aalst

B-9000

Universitair Ziekenhuis Gent, Ghent

B-3000

U.Z. Gasthuisberg, Leuven

5211 NL

Jeroen Bosch Ziekenhuis, 's-Hertogenbosch

1091 HA

Onze Lieve Vrouwe Gasthuis, Amsterdam

1105 AZ

Akademisch Medisch Centrum, Amsterdam

6500 HB

University Medical Center Nijmegen, Nijmegen

3075 EA

Daniel Den Hoed Cancer Center at Erasmus University Medical Center, Rotterdam

3584 CX

Academisch Ziekenhuis Utrecht, Utrecht

G61 1BD

Beatson Institute for Cancer Research - Glasgow, Glasgow

All Listed Sponsors

collaborator

University of Glasgow

OTHER

lead

European Organisation for Research and Treatment of Cancer - EORTC

NETWORK